Merck KGaA Reports P-III Trial (JAVELIN Bladder 100) Results of Bavencio (avelumab) in 1L Maintenance Treatment for Advanced Urothelial Carcinoma
Shots:
- The P-III trial (JAVELIN Bladder 100) evaluating BAVENCIO + BSC vs BSC alone in 700 patients. The results reinforce the proven survival benefits, patients had an m-OS (29.7 vs 20.5mos.) in the overall population as measured from the start of 1L CT
- Similar OS benefits were observed for patients who were progression-free following either carboplatin or cisplatin-based CT. Patients who received cisplatin + gemcitabine & carboplatin + gemcitabine; m-OS (31.0 vs 23.0mos.) & (25.8 vs 17.6mos.), long-term safety was similar in groups with no new safety concerns, grade ≥3 TRAEs (16% & 23%) for cisplatin & carboplatin cohorts
- The company highlighted additional results incl. updates from real-world studies of patient populations in France, Italy, Germany & the US
Ref: Businesswire | Image: Merck
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
